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most expensive screening program in term of population ECs is TIR/TIR/ADN. How-
ever, this strategy has the lowest EC/neonate with CF. In the opposite TIR/ADN has
the lowest EC in term of population but the highest cost in term of neonates with
CF. However more data are needed in order to increase the power of estimations. It
is clear that the factors which have most influences in cost difference between
regions are algorithm type used, order of diagnostic tests and cutoff points.
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OBJECTIVES: Migraine is associated with significant medical costs in Western
countries. However, there is currently limited information comparing the eco-
nomic burden of different types of migraine including chronic migraine (CM) (15
headache days/month), especially in Asia. This study aims to estimate the medical
costs associated with chronic migraine in Taiwan. METHODS: A retrospective
matched cohort study was conducted utilizing data from the Taiwan National
Health Insurance Research Database. Cases of chronic migraine were defined as
patients with  one neurological outpatient visit with primary or secondary ICD-
9-CM code of 346.11, diagnosed by neurologists in medical centers during 2007-
2008. The 1st comparison group was other migraine sufferers (346.XX), without any
migraine diagnosis before 2007, matched with cases at a 4:1 ratio by age, gender,
and hospital setting. The 2nd comparison group was the general population with-
out any migraine diagnosis during 2005-2009, matched with cases at a 4:1 ratio by
age, gender, urbanization level of the residence and income. Medical costs within
365 days after the index date were assessed using a two-part model: a logistic
regression to predict the probability of use of services and a generalized linear
model to predict utilization for users of services. RESULTS:A total of 723 and 727 of
CM patients were matched with 2384 of other migraine sufferers and 2906 of the
general population, respectively. Patient with CM had significantly higher total
medical costs versus those with other migraine (NT$52527 vs. NT$41886,
differenceNT$10641; p0.001) or the general population (NT$61018 vs. NT$21377,
differenceNT$39641; p0.001). The mean drug costs for CM sufferers were higher
than those with other migraine (NT$16617 vs. NT$11217, differenceNT$5400;
p0.001) or the general population (NT$19691 vs. NT$7105, differenceNT$12586;
p0.001). CONCLUSIONS: Consistent with a higher burden of illness, CM sufferers
in Taiwan had significantly higher medical costs than those with other migraine
diagnoses or the general population.
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OBJECTIVES: The information on Sclerosis Multiplex (MS) health care and social
expenditures is not publicly available in Slovakia. The objective of the Cost of
Illness study was to establish the current cost of MS in order to provide a basis upon
which the economic impact of new treatments can be estimated. METHODS: The
analysis was performed based on the several data sources. Information on health-
care and social expenditure were obtained from State Health and Social Insurance
Funds. As not all detailed data on expenditures were available in a necessary struc-
ture, the missing data were collected in the patient research. Both direct and indi-
rect costs were evaluated and dissagregated by the cost type and severity of the
disease based on the EDSS score. Capital method is the most common method
applied for calculation of Indirect costs in MS and it was used in order to get
comparison with the data published in other countries. RESULTS: In Slovakia, the
prevalence of MS is 112/100 thousands inhabitans. Total yearly MS expenditures in
2010 were 40,7 mill. EUR. Direct costs counted for 57% of total costs and the most of
them (95%) were caused by drugs, hospitalisations and diagnostics (mostly MRI)
expenditures. The highest share of Indirect costs represented Loss of productivity
(58%), followed by Disability pensions (37%) and Sick leave wage compensation
(4%). Direct and indirect costs per one patient represent 3770 Eur and 2896 Eur
respectively.CONCLUSIONS:The evidence of cost-effectiveness of new treatments
must be demonstrated in order to get reimbursement in Slovakia. According the
Slovak Guidelines only direct costs are accepted in cost-effectiveness submissions
and indirect costs are taken into account only in reasonable cases. Indirect costs
represent nearly half of total MS costs (43%) and therefore should be considered in
assessing the cost effectiveness of new comming innovative MS therapies.
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OBJECTIVES: A Multiple Sclerosis (MS) relapse refers to an episode of neurological
disturbance during which an acute worsening of function occurs, usually lasting
for several days or weeks. The TRIBUNE study provides a detailed exploration of
costs and quality of life (QoL) associated with MS relapses. METHODS: Patients in
five European countries (France, Germany, Italy, Spain, and UK) completed a self-
administered web-based questionnaire capturing information on demographics,
disease characteristics and severity (EDSS), co-morbidities, relapses, resource con-
sumption, and relevant aspects of QoL. The effect of relapses on the socioeconomic
burden was assessed by the difference in costs and QoL incurred by relapsing-
remitting MS (RRMS) patients with and without relapse(s) with EDSS score 5.
RESULTS: Out of 1261 patients that completed the questionnaire, 68% had RRMS
and 87% reported receiving MS treatment. Nearly half (48%) of the RRMS patients
with an EDSS score  5 reported having at least one relapse during the past year.
This sub-group reported a higher consumption of direct medical resources, profes-
sional and informal care, and more sick-leave days compared to patients without
relapse(s). The difference in costs of patients with relapse(s) compared to those
without ranged between €3,321 and €9,430 across countries. Relapses requiring
treatment with steroids or hospitalization resulted in higher costs compared with
relapses not needing an intervention; €4,062 - €10,589 versus €340 - €5,096 respec-
tively across countries. QoL outcomes were also correlated with relapse(s).
CONCLUSIONS: The additional burden imposed by relapses is important both in
terms of excess cost and the impact on quality of life. The use of effective treat-
ments that reduce the frequency of relapses, in addition to providing clinical ben-
efits, could potentially lessen the clinical and socioeconomic burden of MS.
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OBJECTIVES: Muscular dystrophies (MD) are a group of genetically heterogeneous
disorders, characterized by progressive muscle wasting and weakness. The MDs
vary in incidence, pattern of inheritance, age of onset (though frequently among
pediatrics), muscles affected, and progression. Overall, MD imposes a significant
economic burden on both patients and society in general. This study assessed
recent trends in pediatric MD hospitalizations in the United States (US).METHODS:
Data for pediatric (20 years) hospitalizations with a primary diagnosis of MD
(ICD-9-CM codes 359.0, 359.1, or 359.2) from the 1997, 2000, 2003, and 2006 HCUP
Kids’ Inpatient Databases, nationally representative databases of pediatric hospi-
talizations in the US, were analyzed. Weighted estimates of the number of hospi-
talizations for MD, characteristics of these hospitalizations (e.g., patient demo-
graphics), and associated resource-based measures (i.e., charges, length of stay
[LOS], and most common primary procedures performed) were derived. RESULTS:
Between 1997 and 2006, the rate of pediatric MD-related hospitalizations (per
100,000 2010 US pediatric population) has increased, from 3.57/100,000 in 1997 to
4.12/100,000 in 2000, 4.39/100,000 in 2003, and 4.56/100,000 in 2006. Mean LOS de-
creased appreciably between 1997 and 2000, then remained unchanged through
2006 (10.7 days in 1997, and 9.4 days in 2000, 2003, and 2006). During each year of the
study period, continuous mechanical ventilation and dorsal and dorsolumbar fu-
sion (posterior technique) were the most frequently observed primary procedures.
Finally, mean total charges (2010 US $) for MD-related stays increased roughly 21%,
from $53,739 (1997) to $65,280 (2006). CONCLUSIONS: We examined rates of pedi-
atric MD-related hospitalizations in the US, and observed an increase in the rate of
hospitalizations over time. LOS decreased from 1997 to 2000, then remained con-
stant through 2006, although total charges increased significantly over this time.
These findings provide insight into MD-related hospitalizations in the US and high-
light the need to further examine the burden of MD.
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OBJECTIVES: Multiple sclerosis (MS) is a prevalent, chronic and disabling disease,
affecting mainly young adults. The most common clinical form presents with re-
current episodes of focal neurological deficits, called relapses. The aim of this work
is to analyse the socioeconomic cost of an MS relapse. METHODS: A prospective
observational study performed in 2 MS Units, located in Barcelona (Spain). We
included 100 consecutive patients (april 2007 to november 2009) who have had a
relapse. Patients were invited to answer a questionnaire after the relapse, with
demographic, social, employment status data and clinical aspects, as well as data
about the consumption of sanitary and no-sanitary resources during the relapse.
The unit costs were calculated according to the Catalan Health Service. RESULTS:
The mean age was 38.3 years, and 2 out of 3 were female sex. The mean duration of
disease was 9.5 years. 94% of patients had recurrent-remitting MS and secondary-
progressive 6%. At the time of the relapse 76% had a mild disability, 22% modeate
and 2% severe. 63% of patients reported to be employed. The relapse required a
mean of 3.1 medical visits, 3.7 days of outpatient hospitalization, 22.5 hours for
informal care and 12.4 sick leave days. The MS relapse costs resulted 2.609 euros
per patient. This included 1.524 euros of direct costs (medical visits: 183,7 euros,
complementary tests: 28,5 euros, hospitalizations days: 32,5 euros, outpatient hos-
pitalization:777,8 euros, displacements:152,9 euros, rehabilitation: 98,9 euros, in-
formale care: 151,7 euros, formal care: 21,5 euros and treatment: 76,5 euros) and
1.085 euros of indirect costs (sick leave days). CONCLUSIONS: Total cost of MS
relapse resulted (included direct and indirect costs) 2.609 euros per patient. The
main contributors to total cost were sick leaves and outpatient hospitalization.
PND20
A COST-OF-ILLNESS ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS IN
GREECE
Athanasakis K1, Sideris M1, Zacharis M2, Rentzos M2, Evdokimidis I2, Kyriopoulos J1
1National School of Public Health, Athens, Greece, 2Aeginition University Hospital, National and
Kapodistrian University, Athens, Attica, Greece
A320 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
